Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 308-783-3 | CAS number: 98510-75-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1987-01-13 to 1987-02-13
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read-across from a study comparable to guideline with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 987
- Report date:
- 1987
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Principles of method if other than guideline:
- Mammalian erythrocyte micronucleus test as described by described by W. Schmid - The Micronucleus test, Mutation Research, 31, 9-15 (1975), the later released OECD Guideline 474 (1983) is based to a great extend on this publication.
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- C8-18 and C18 unsatd. AAPB (Coco AAPB)
- IUPAC Name:
- C8-18 and C18 unsatd. AAPB (Coco AAPB)
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: OF1 (I. O. P. S. Caw)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: no data
- Weight at study initiation: no data
- Assigned to test groups randomly: animals were not formally randomized
- Fasting period before study: no data
- Housing: 2 (preliminary study) or 5 (main study) in plastic cages, on dust free bedding
- Diet: ad libitum, commercial pelleted diet UAR - A04C-R
- Water: ad libitum from plastic bottles
- Acclimation period: minimum 24 h
ENVIRONMENTAL CONDITIONS
- Temperature: 22 °C +/- 1.5 °C
- Humidity: relative humidity 55 +/- 15%
- Air changes): minimum of 8 air changes per hour
- Photoperiod: 12 h light / 12 h dark cycle
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- - Vehicle(s)/solvent(s) used: sterile distilled water. The pure compound and all dilutions were kept at 4°C during the test.
- Details on exposure:
- Preliminary study:
- No. of animals per dose: 2 males/2 females
- Frequency of treatment: two times; 24 h between injections
- Doses: 100, 200, 500, 1000, 2000 mg/kg bw i.p.
- Time of sacrifice: 6 hours after second injection
- Observation time points: 15 min after first administration, then periodically up to 30 hours.
- Type of observations: clinical signs, mortality
- Tolerated doses: 100 - 500 mg/kg bw
Main study
- No. of animals per dose: 5 males/5 females
- Frequency of treatment: two times; 24 h between injections
- Doses: 20, 200 mg/kg bw i.p., injected volume: each 10 ml/kg bw
- Positive control: cyclophosphamide 100 mg/kg bw i.p., injected volume: each 10 ml/kg bw
- Negative control: sterile distilled water, injected volume 10 ml/kg bw
- Time of sacrifice: 6 hours after second injection by cervical dislocation
- Number of samples: two smears of bone marrow/each animal
- EXAMINATIONS: Number of cells with micronuclei / 1000 polychromatic erythrocytes (PCE/NCE ratio: not given)
- Duration of treatment / exposure:
- 30 hours
- Frequency of treatment:
- Two times, 24 h between the two injections
- Post exposure period:
- 30 h after first injection
6 h after second injection
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 20, 200 mg/kg bw /injection (two injections at an interval of 24 h)
Basis:
nominal conc.
- No. of animals per sex per dose:
- Preliminary study: 2 males, 2 females
Main study: 5 males, 5 females - Control animals:
- yes
- Positive control(s):
- Cyclophosphamide, 5 males and 5 females
- Doses / concentrations: 100 mg/kg bw
Examinations
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
preliminary study (details see "any other information on materials and methods")
In this preliminary study the test animals were administered twice (in a 24 hours interval) each 100, 200, 500, 1000 and 2000 mg/kg bw/day by intraperitoneal injection. Clinical signs and mortality were observed up to 30 hours after the first administration. Clinical signs like piloerection and ptosis were seen at doses of >/= 100 mg/kg bw/day. At doses >/= 1000 mg/kg bw/day the mice died within 30 and 4 hours after the first administration. The tolerated doses were in the range of 100 to 500 mg/kg bw/day. Therefore, the dose of 200 mg/kg bw/day was selected as the high dose and 20 mg/kg bw/day (10 % of the high dose) as the low dose. The dose level of 200 mg/kg bw/day (corresponding to 60 mg active substance/kg bw/day) is considered to be sufficiently high based on the effects found in the preliminary study and due to the highly irritating properties of the compound.
TREATMENT AND SAMPLING TIMES (in addition to information in specific fields): As the test substance was applied twice with a 24 h interval (although only one timepoint was chosen for sacrifice), the result of the sacrifice 6h later may be regarded as a result of a 30h and a 6h treatment.
DETAILS ON SMEAR PREPARATION: The bone marrow was extracted from the femurs using foetal calf serum centrifuged and put into suspension again. For each animal, two smears were prepared, air-dried and stained with freshly filtered May Grunwald and Giemsa staining. - Statistics:
- Student´s test
Exact bilateral comparison test
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- in preliminary dose finding study lethal at doses >/= 1000 mg/kg bw
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
Any other information on results incl. tables
Preliminary study:Clinical signs:
Mortality:1000 mg/kg bw: 4/4 animals died within 30 hours after first administration 2000 mg/kg bw: 4/4 animals died within 4 hours after first administration
>= 100 mg/kg bw: piloerection
>= 500 mg/kg bw: ptosis
1000 mg/kg bw: loss of righting reflex
Main study:
Mean numbers of micronucleated erythrocytes/1000 polychromatic erythrocytes:
- 20 mg/kg bw: 0.8, Sd dev 0.7 (males), 1.6 Sd dev 1.5 (females)
- 200 mg/kg bw: 1.2 Sd dev 1.0 (males), 1.0 Sd dev 1.3 (females)
- Negative control (vehicle sterile distilled water): 1.4 Sd dev 0.8 (males), 1.8 Sd dev 2.2 (females)
- Positive control (cyclophosphamide): 67.8 Sd dev 11.9 (males), 44.8 Sd dev 7.7 (females)
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): negative
No significant increase in the number of micronucleus-bearing erythrocytes was observed following two intraperitoneal administration of Coco AAPB (a.i.: 30 % ). The results for each treated group were comparable with those obtained for the negative control group. The results obtained with cyclophosphamide positive control (100 mg/kg) are significantly positive. Test article Coco AAPB induced no mutagenic effect in the mouse. - Executive summary:
In a OF1 (I.O.P.S. Caw) mouse bone marrow micronucleus assay, performed as described by W. Schmid - The Micronucleus test, Mutation Research, 31, 9-15 (1975), 5 male and 5 female animals were treated i. p. with Coco AAPB (30 % a.i). The test method by W. Schmidt is almost equivalent to the procedure described by OECD guideline 474. In a preliminary study the test animals were administered twice (in a 24 hours interval) each 100, 200, 500, 1000 and 2000 mg/kg bw/day by intraperitoneal injection. Clinical signs and mortality were observed up to 30 hours after the first administration. Clinical signs like piloerection and ptosis were seen at doses of >/= 100 mg/kg bw/day. At doses >/= 1000 mg/kg bw/day the mice died within 30 and 4 hours after the first administration. The tolerated doses were in the range of 100 to 500 mg/kg bw/day. Therefore, the dose of 200 mg/kg bw/day was selected as the high dose and 20 mg/kg bw/day (10 % of the high dose) as the low dose. As the test substance was applied twice with a 24 h interval (although only one timepoint was chosen for sacrifice), the result of the sacrifice 6h later may be regarded as a result of a 30h and a 6h treatment. The dose level of 200 mg/kg bw/day (corresponding to 60 mg active substance/kg bw/day) is considered to be sufficiently high based on the effects found in the preliminary study and due to the highly irritating properties of the compound.
The mean number of micronucleated erythrocytes/1000 polychromatic erythrocytes in males and female mice at 20 and 200 mg/kg bw/day were unaffected compared to the negative controls. The administration of 100 mg cyclophosphamide/kg bw serving as the positive control led to clearly elevated numbers of micronucleated erythrocytes.
It can be concluded, that Coco AAPB (30 % a.i) induced no clastogenic effect in this in vivo cytogenicity study on mice at dose levels of 20 and 200 mg/kg bw/day.
This study is classified as acceptable. This study satisfies the requirement for Test Guideline OECD 474 for in vivo cytogenetic mutagenicity data.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
